𝔖 Bobbio Scriptorium
✦   LIBER   ✦

No evidence for genetic association of interferon regulatory factor 1 in juvenile idiopathic arthritis

✍ Scribed by Mark S. Fife; Laura Gathercole; Emma M. Ogilvie; Carmel J. W. Stock; Lisa F. Mack; Rachelle P. Donn; Wendy Thomson; Patricia Woo


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
262 KB
Volume
56
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

Juvenile idiopathic arthritis (JIA) comprises several clinically distinct subgroups and is the most widespread cause of chronic childhood disability. A significant association between JIA and a polymorphism in the interferon regulatory factor 1 (IRF‐1) gene has previously been reported, implicating IRF1 in disease susceptibility. The aim of this study was to replicate the IRF1 association in JIA using single‐marker and haplotype analyses in a case–control study, using control subjects different from those in the previous study and a larger cohort of patients (n = 765).

Methods

DNA from 765 patients with JIA and 508 unaffected control subjects was genotyped for 4 single‐nucleotide polymorphisms in the IRF‐1 gene. Association of genotypes at the IRF1 loci was assessed using single‐marker and haplotype analyses.

Results

No significant differences in genotype frequency or allele frequency were observed between patients and control subjects.

Conclusion

This replication study used a much larger patient cohort to examine the association of IRF1 in JIA. However, despite the increased statistical power, we observed no significant association for IRF1 markers, either individually or as haplotypes. It is therefore unlikely that this gene is involved in JIA susceptibility.


📜 SIMILAR VOLUMES


No evidence of association between anti–
✍ Mark Lunt; Kath D. Watson; William G. Dixon; British Society for Rheumatology Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

## Objective To study the association between anti–tumor necrosis factor (anti-TNF) therapy and mortality in a national cohort of patients with rheumatoid arthritis. ## Methods We prospectively followed up 12,672 patients who were beginning anti-TNF therapy and 3,522 biologic-naive patients recei